Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPX-200
- Development stage
- Preclinical
- Lead developer
- OrthoTrophix
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
TPX-200 is a preclinical-stage phosphatonin protein being developed by OrthoTrophix for the treatment of chronic kidney disease-related conditions, including chronic kidney disease-mineral and bone disorder (CKD-MBD), hyperphosphatemia, and hyperparathyroidism. The drug is based on matrix extracellular phosphoglycoprotein (MEPE), a member of the SIBLING (Small Integrin-Binding Ligand, N-linked Glycoprotein) protein family that plays a critical role in phosphate homeostasis and bone mineralization. TPX-200 is designed as a phosphate-regulating peptide that aims to improve both bone strength and kidney function by modulating phosphate metabolism. It represents a potential first-in-class therapeutic approach to addressing the systemic mineral imbalances and bone health issues associated with advancing chronic kidney disease.
- Other names
- Matrix extracellular phosphoglycoproteinMEPEphosphatonin protein
02
Targets
MTNR1A (MT1)
Beyond the preview
Go deeper on TPX-200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TPX-200.